D. Boral Capital restated their buy rating on shares of ImmunityBio (NASDAQ:IBRX - Free Report) in a research note published on Friday morning,Benzinga reports. The firm currently has a $30.00 target price on the stock.
Separately, BTIG Research assumed coverage on shares of ImmunityBio in a research note on Friday, January 10th. They set a "buy" rating and a $6.00 target price on the stock.
Check Out Our Latest Stock Analysis on IBRX
ImmunityBio Stock Up 6.0 %
IBRX traded up $0.17 during trading on Friday, hitting $3.02. The company's stock had a trading volume of 8,891,818 shares, compared to its average volume of 6,448,118. The business's 50 day simple moving average is $3.02 and its 200-day simple moving average is $3.73. The firm has a market cap of $2.10 billion, a PE ratio of -3.28 and a beta of 0.94. ImmunityBio has a one year low of $2.28 and a one year high of $10.53.
ImmunityBio (NASDAQ:IBRX - Get Free Report) last released its quarterly earnings results on Monday, March 3rd. The company reported ($0.15) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.26) by $0.11. The company had revenue of $7.55 million for the quarter, compared to the consensus estimate of $8.74 million. Equities research analysts expect that ImmunityBio will post -0.92 EPS for the current fiscal year.
Institutional Trading of ImmunityBio
Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Stephens Inc. AR bought a new position in shares of ImmunityBio during the 4th quarter valued at about $26,000. Cibc World Markets Corp bought a new stake in shares of ImmunityBio during the fourth quarter valued at approximately $35,000. Maia Wealth LLC bought a new stake in shares of ImmunityBio in the fourth quarter valued at about $37,000. GF Fund Management CO. LTD. purchased a new stake in shares of ImmunityBio in the 4th quarter worth approximately $37,000. Finally, Schechter Investment Advisors LLC purchased a new position in shares of ImmunityBio in the 4th quarter valued at $38,000. Institutional investors own 8.58% of the company's stock.
About ImmunityBio
(
Get Free Report)
ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.
See Also
Before you consider ImmunityBio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ImmunityBio wasn't on the list.
While ImmunityBio currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
